The Data Monitoring Experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity Program

Stuart Pocock, Duolao Wang, Lars Wilhelmsen and Charles H. Hennekens
Additional contact information
Stuart Pocock: London School of Hygiene and Tropical Medicine, Medical Statistics Unit
Duolao Wang: London School of Hygiene and Tropical Medicine, Medical Statistics Unit
Lars Wilhelmsen: Göteborg University, Section of Cardiology, The Cardiovascular Institute
Charles H. Hennekens: University of Miami School of Medicine and Florida Atlantic University

Chapter Case 11 in Data Monitoring in Clinical Trials, 2006, pp 166-175 from Springer

Abstract: Abstract The Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program was designed as three separate randomized trials comparing candesartan with placebo in patients with chronic heart failure (CHF) who (1) were intolerant to angiotensin converting enzyme (ACE)-inhibitor and had left ventricular ejection fraction (LVEF) ≤ 40%, (2)) were on ACE-inhibitor and had LVEF ≤ 40% or (3)) had LVEF > 40%. CHARM provides an interesting example of the challenges faced by a Data and Safety Monitoring Committee (DSMC). While the primary efficacy endpoint for each component trial was cardiovascular (CV) death or hospitalization for CHF, the primary outcome for the overall program was all-cause mortality. The DSMC received monthly safety reports and also met every six months (seven times in all) to review interim reports. Statistical stopping guidelines were predefined for all-cause mortality in the overall program. The overarching principle of the DSMC was proof beyond a reasonable doubt that would be likely to influence clinical practice. There were significant treatment differences in all-cause mortality at several interim analyses, and the statistical stopping guideline was reached on one occasion. The DSMC consistently recommended that the program continue as planned. The final published results for all-cause death over a median 3.1 years were a 9%; reduction in hazard (95%; CI 0%; to 17%;, p = 0.055), whereas for CV death or hospitalization for CHF there was a 16%; reduction in hazard (95%; CI 9%; to 23%; p

Keywords: Angiotensin Converting Enzyme; Chronic Heart Failure; Interim Analysis; Reasonable Doubt; Interim Report (search for similar items in EconPapers)
Date: 2006
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-0-387-30107-5_15

Ordering information: This item can be ordered from
http://www.springer.com/9780387301075

DOI: 10.1007/0-387-30107-0_15

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().